↓ Skip to main content

High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins

Overview of attention for article published in Arthritis Research & Therapy, June 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins
Published in
Arthritis Research & Therapy, June 2015
DOI 10.1186/s13075-015-0672-8
Pubmed ID
Authors

Alexandre W. S. de Souza, Kornelis S. M. van der Geest, Elisabeth Brouwer, Frederico A. G. Pinheiro, Ana Cecília Diniz Oliveira, Emília Inoue Sato, Luis Eduardo C. Andrade, Marc Bijl, Johanna Westra, Cees G. M. Kallenberg

Abstract

Takayasu arteritis (TA) and giant cell arteritis (GCA) are large vessel vasculitides (LVV) which usually present as granulomatous inflammation in arterial walls. High mobility group box-1 (HMGB1) is a nuclear protein that acts as an alarmin when released by dying or activated cells. This study aims to evaluate whether serum HMGB1 can be used as a biomarker in LVV. Twenty nine consecutive TA patients with 29 healthy controls (HC) were evaluated in a cross-sectional study. Eighteen consecutive GCA patients with 16 HC were evaluated at the onset of disease and in part of them during follow-up. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay. In GCA patients at disease onset mean serum HMGB1 levels did not differ from HC (5.74 ± 4.19 ng/ml vs. 4.17 ± 3.14 ng/ml; p = 0.230). No differences in HMGB1 levels were found between GCA patients with and without polymyalgia rheumatica (p = 0.167), ischemic manifestations (p = 0.873), systemic manifestations (p = 0.474) or relapsing disease (p = 0.608). During follow-up, no significant fluctuations on serum HMGB1 levels were observed from baseline to 3 months (n = 13) (p = 0.075), 12 months (n = 6) (p = 0.093) and at the first relapse (n = 4) (p = 0.202). Serum HMGB1 levels did not differ between TA patients and HC [1.19 (0.45-2.10)ng/ml vs. 1.46 (0.89-3.34)ng/ml; p = 0.181] and no difference was found between TA patients with active disease and in remission [1.31 (0.63-2.16)ng/ml vs. 0.75 (0.39-2.05)ng/ml; p = 0.281]. HMGB1 levels were significantly lower in 16 TA patients on statins compared with 13 patients without statins [0.59 (0.29-1.46)ng/ml vs. 1.93 (0.88-3.34)ng/ml; p = 0.019]. Age was independently associated with higher HMGB1 levels regardless of LVV or control status. Patients with TA and GCA present similar serum HMGB1 levels compared with HC. Serum HMGB1 is not useful to discriminate between active disease and remission. In TA, use of statins was associated with lower HMGB1 levels. HMGB1 is not a biomarker for LVV.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 4%
Unknown 25 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 19%
Other 4 15%
Student > Postgraduate 3 12%
Student > Ph. D. Student 3 12%
Librarian 2 8%
Other 5 19%
Unknown 4 15%
Readers by discipline Count As %
Medicine and Dentistry 12 46%
Biochemistry, Genetics and Molecular Biology 2 8%
Psychology 2 8%
Immunology and Microbiology 1 4%
Computer Science 1 4%
Other 5 19%
Unknown 3 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2016.
All research outputs
#9,968,371
of 12,451,992 outputs
Outputs from Arthritis Research & Therapy
#1,716
of 1,983 outputs
Outputs of similar age
#161,111
of 234,102 outputs
Outputs of similar age from Arthritis Research & Therapy
#24
of 32 outputs
Altmetric has tracked 12,451,992 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,983 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,102 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.